The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection.

ABSTRACT:

Background and objectives

Convalescent plasma has attracted significant attention as a therapeutic option against infectious agents for more than a century. In March 2020, the use of Convalescent COVID-19 plasma (CCP) as a new research drug for COVID-19 treatment was approved by the FDA. The development of SARS-CoV-2 IgG antibodies following infection or vaccination is likely to be essential to provide adequate immunity for the population to halt the COVID19 pandemic. This study aimed to identify the criteria that would be used to determine the most appropriate CCP donors with the highest effective antiviral antibody titers.

Materials and methods

In this prospective cohort, univariate analyses and multivariate regression analyses were performed to evaluate the relationship b

SUBMITTER: Fazeli A 

PROVIDER: S-EPMC8554042 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature